[[Cobimetinib]]

CATEGORIES: Experimental cancer drugs, Protein kinase inhibitors

Cobimetinib (GDC-0973, XL-518) is a MEK inhibitor being developed by Exelixis and Roche. It is being studied in combination with vemurafenib to treat several cancers, including melanoma.

==References==


